Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline results from its Phase 3 ARTISTRY-1 trial for an investigational HIV ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

The Pennsylvania Department of Health will cut 25% of funding to the Part B of the Ryan White HIV/AIDS Program amid rising ...

Despite Uganda's steady progress in reducing HIV infections and AIDS-related deaths, men remain disproportionately affected due to low uptake of antiretroviral treatment (ARVs), the Uganda AIDS ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

A Thai man accused a gay man in the central province of Saraburi of spreading HIV within the LGBTQIA+ community and trading ...

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...

A Jacobs School of Medicine and Biomedical Sciences faculty member is senior author on a newly published study on the public health challenges of HIV in Nigeria.

Administration officials say South Africa has “significant means” to fund a promising new drug, lenacapavir, on its own.